Meeting
2018 Genitourinary Cancers Symposium
Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC).
Authors
Justine Ku
Prostate Oncology Specialists, Marina Del Rey, CA
Justine Ku , Kirk Wilenius , Claire Larsen , Kyle De Guzman , Steven Yoshinaga , Jeffrey S. Turner , Richard Y. Lam , Mark C. Scholz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 368)
DOI
10.1200/JCO.2018.36.6_suppl.368
Abstract #
368
Poster Bd #
E15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2019 Genitourinary Cancers Symposium
Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Marcus Marie Moses
Poster
2019 Genitourinary Cancers Symposium
EphB4-EphrinB2 receptor-ligand pair as a novel target in prostate cancer (PC).
First Author: Sarmad Sadeghi
Poster
2018 Genitourinary Cancers Symposium
Pembrolizumab for recurrent or advanced prostate cancer.
First Author: Juliana Higa